Share on StockTwits
 

Perrigo (NASDAQ:PRGO) has earned an average rating of “Buy” from the sixteen ratings firms that are currently covering the company, American Banking News.com reports. Four investment analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $151.97.

Perrigo (NASDAQ:PRGO) traded up 0.90% on Monday, hitting $147.0575. 818,300 shares of the company’s stock traded hands. Perrigo has a one year low of $109.02 and a one year high of $162.35. The stock’s 50-day moving average is $154.5 and its 200-day moving average is $139.1. The company has a market cap of $14.514 billion and a P/E ratio of 54.50.

Perrigo (NASDAQ:PRGO) last posted its quarterly earnings results on Thursday, February 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.59 by $0.28. The company had revenue of $979.00 million for the quarter, compared to the consensus estimate of $996.68 million. During the same quarter in the previous year, the company posted $1.36 earnings per share. The company’s revenue for the quarter was up 10.9% on a year-over-year basis. On average, analysts predict that Perrigo will post $6.62 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which is scheduled for Tuesday, March 18th. Investors of record on Friday, February 28th will be given a dividend of $0.105 per share. This represents a $0.42 dividend on an annualized basis and a yield of 0.29%. The ex-dividend date of this dividend is Wednesday, February 26th.

PRGO has been the subject of a number of recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of Perrigo in a research note to investors on Friday. They now have a $154.00 price target on the stock. Separately, analysts at B. Riley downgraded shares of Perrigo from a “buy” rating to a “neutral” rating in a research note to investors on Friday. They noted that the move was a valuation call. Finally, analysts at Argus raised their price target on shares of Perrigo from $160.00 to $175.00 in a research note to investors on Thursday, January 16th. They now have a “buy” rating on the stock.

Perrigo Company is a global healthcare supplier that develops, manufactures and distributes over-the-counter (NASDAQ:PRGO) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products and active pharmaceutical ingredients (API).

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.